

APPLICATIONS

Simultaneous Determination of Antidepressants and Metabolites in Urine Using Ultra-High Performance Liquid Chromatography – Tandem Mass Spectrometry (UHPLC-MS/MS) using a Kinetex[®] Core-Shell C18 HPLC/UHPLC Column

Aixia Sun, Cheng Fang, and Roger Brown¹, Erica Pike and Brian Rivera²,

¹American Clinical Solutions, Sun City Center, FL 33573 USA ²Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Introduction

Antidepressants are drugs used to treat clinical depression, as well as anxiety disorders. According to the pharmacological mechanism of action (MOA), antidepressants are divided into seven classes. These include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI's) and serotonin and norepinephrine reuptake inhibitors (SNRI's). Patients taking antidepressants can experience toxicity and severe side effects. This is especially true with tricyclic antidepressants (TCA's), which have severe morbidity and mortality rates. As such, it is imperative to evaluate patient adherence as well monitor abuse.

Although clinical laboratories can use immunoassay to evaluate antidepressant dosage and misuse, LC/MS/MS methodology is preferred because of its selectivity and robustness. In this study, a simple sample preparation procedure and a rapid, sensitive, specific Ultra-High Performance Liquid Chromatography – Tandem Mass Spectrometry (UHPLC-MS/MS) method has been developed for quantifying several antidepressants, including amitriptyline, bupropion, citalopram, clomipramine, doxepin, duloxetine, fluoxetine, imipramine, paroxetine, and venlafaxine as well as five major metabolites, nortriptyline, norfluoxetine, desipramine, hydroxybupropion, and o-desmethylvenlafaxine, in human urine samples.

Reagents and Chemicals

Primary reference standards and deuterated internal standards were purchased (Cerilliant Corporation, Round Rock, TX). A mixture of standard solution was prepared in acetonitrile and then added to drug-free urine to make multi-concentration levels of calibrators. The internal standards mixture includes amitriptyline-d3, clomipramine-d3, desipramine-d3, doxepin-d3, imipramine-d3, nortriptyline-d3, bupropion-d9, fluoxetine-d6, paroxetine-d6, and venlafaxine-d6, and it was prepared in acetonitrile and added in urine samples, standards, and controls.

Sample Preparation

A simple “dilute and shoot” urine sample extraction was carried out by a Tomtec[™] Quadra 4[™] liquid handler (Hamden, CT) in 96-well collection plates to increase throughput. Samples were treated with beta-glucuronidase to hydrolyze glucuronide conjugates, followed by dilution and centrifugation.

LC/MS/MS Conditions

LC/MS/MS was performed using a Kinetex[®] 2.6 μ m core-shell C18 50 x 3.0mm HPLC/UHPLC column and a Shimadzu[®] Nexera[™] UHPLC system (Kyoto, Japan) with an upper pressure limit of 1300 bar. A triple quadrupole API 3200[™] system (AB SCIEX, Framingham, MA), equipped with an electrospray source, was used for mass spectrometric detection. The MS spectra were recorded in multiple-reactions monitoring and scheduled MRM[™] algorithm. MRM Transitions and Ionization Source Parameters are listed in **Table 1**.

Analytical Method


Column:	Kinetex [®] 2.6 μ m C18	
Dimensions:	50 x 3.0 mm	
Part No.:	00B-4462-Y0	
Mobile Phase:	A: 2 mM Ammonium acetate with 0.075% (v/v) acetic acid (pH 4.5) B: 2 mM Ammonium acetate with 0.075% (v/v) acetic acid and acetonitrile	
Flow Rate:	0.8 mL/min	
Temperature:	Ambient	
Instrument:	Shimadzu Nexera UHPLC	
Detector:	AB SCIEX API 3200 [™] MS/MS, ESI+	
Gradient:	Time (min)	% B
	0.0	18
	0.40	18
	1.10	45
	1.70	60
	2.10	95
	2.50	95
	2.54	18
	3.50	18
Ionization Source Parameters:		
Gas 1 & Gas 2	50	
CAD	6	
Cur	35	
IS	3000	
Temp	550	



Table 1.
MRM Transitions & Retention Times

Analyte Peak Name	Q1	Q3	Analyte Retention Time (min)
Amitriptyline	278.0	91.0	2.29
Bupropion	240.1	184.1	1.88
Citalopram	325.1	109.1	2.03
Clomipramine	315.1	86.2	2.42
Desipramine	267.1	208.2	2.17
<i>o</i> -Desmethylvenlafaxine	264.1	107.2	1.27
Doxepin	280.0	107.1	2.08
Duloxetine	298.0	154.2	2.21
Fluoxetine	310.1	148.0	2.30
Hydroxybupropion	256.1	238.1	1.57
Imipramine	281.0	86.2	2.23
Norfluoxetine	296.0	134.1	2.24
Nortriptyline	264.1	233.2	2.22
Paroxetine	330.0	192.2	2.12
Venlafaxine	278.1	260.2	1.81

Figure 1.
Representative chromatogram for ten antidepressants and five of their major metabolites



Results

Linearity was evaluated by analyzing samples at 10 concentration levels over the reportable range of assay for three days. Linear Regression using the AnalystTM software (“1 / x*x” weighting) was used to determine slope and correlation coefficient. Results are shown in **Table 2**. Intra-day and inter-day precision and accuracy were determined by analyzing quintuplicate samples at three levels of concentrations. Results are shown in **Table 3** and **Table 4**.

The carry-over was also estimated by injecting blank samples immediately following the highest concentration, and was less than 15 % of lower limit of quantitation (LLOQ), which can be acceptable. Bench-top stability was assessed by reinjection of same samples within 24-48 hours, and was within compliance range. In addition, cross reactivity was investigated against all our current test panels of drugs.

Table 2.
Summary of Reportable Range and Linearity Correlation

Drug	Reportable Range (ng/mL)	Cut-off (ng/mL)	Slope	Linearity Correlation Data (r)	y-intercept
Amitriptyline	278.0	12.5-7500	0.97	0.997	27
Bupropion	240.1	2.5-1500	1.02	0.998	2.45
Citalopram	325.1	2.5-1500	1.04	0.993	3.89
Clomipramine	315.1	12.5-7500	1.11	0.995	2.21
Desipramine	267.1	12.5-7500	1.11	0.998	41.28
<i>o</i> -Desmethylvenlafaxine	280.0	2.5-1500	0.9	0.992	9.04
Doxepin	298.0	12.5-7500	0.89	0.998	69.57
Duloxetine	310.1	12.5-7500	0.94	0.994	32.93
Fluoxetine	256.1	12.5-7500	1.05	0.995	0.95
Hydroxybupropion	281.0	2.5-1500	0.99	0.993	1.05
Imipramine	296.0	12.5-7500	0.94	0.997	31.65
Norfluoxetine	264.1	12.5-7500	1.16	0.998	86.59
Nortriptyline	264.1	12.5-7500	0.88	0.993	85.48
Paroxetine	330.0	12.5-7500	1.03	0.997	14.56
Venlafaxine	278.1	2.5-1500	1.03	0.999	4.54

Table 3.
Intra-day Precision and Accuracy

Drug	Concentration (ng/mL)	Intra-day					
		Day 1		Day 2		Day 3	
		CV (%)	Accuracy (%)	CV (%)	Accuracy (%)	CV (%)	Accuracy (%)
Amitriptyline	100	5.9	109.0	2.7	102.4	5.4	97.0
	250	3.3	109.7	3.4	111.0	4.3	108.9
	750	4.0	102.3	3.0	103.1	7.2	97.8
Bupropion	20	8.7	105.2	7.3	108.9	11.7	94.5
	50	5.5	108.5	5.4	111.4	5.1	109.4
	150	5.8	96.6	6.5	102.2	2.3	101.5
Citalopram	20	6.0	111.4	3.7	104.3	6.8	100.4
	50	5.1	109.7	5.7	110.2	3.9	97.9
	150	4.7	103.6	5.0	105.7	3.9	91.8
Clomipramine	100	2.1	102.2	2.3	103.2	7.4	94.3
	250	3.5	101.5	2.9	105.5	7.4	100.8
	750	4.1	99.7	2.6	106.8	5.0	98.5
Desipramine	100	7.5	101.6	5.0	104.2	5.9	97.4
	250	3.5	107.1	4.5	112.3	6.1	106.1
	750	8.7	98.2	3.4	104.4	4.6	95.9
α -Desmethylvenlafaxine	20	7.3	104.2	1.9	111.4	2.8	100.3
	50	4.0	115.2	1.5	119.1	4.1	113.1
	150	1.0	100.1	2.0	109.0	9.2	103.2
Doxepin	100	0.7	110.8	3.5	108.2	5.6	103.3
	250	3.1	115.4	1.4	118.0	5.0	114.6
	750	0.7	100.4	2.3	106.8	1.9	98.4



Table 3. (continued)
 Intra-day Precision and Accuracy

		Intra-day					
		Day 1		Day 2		Day 3	
Drug	Concentration (ng/mL)	CV (%)	Accuracy (%)	CV (%)	Accuracy (%)	CV (%)	Accuracy (%)
Duloxetine	100	6.8	110.7	7.5	109.6	7.0	105.8
	250	2.2	111.8	6.3	109.9	11.7	111.1
	750	6.1	103.9	5.9	95.3	4.2	105.8
Fluoxetine	100	9.2	100.1	4.3	102.8	7.1	98.1
	250	5.2	95.9	5.5	103.6	5.5	108.1
	750	10.7	98.5	2.5	105.8	3.7	103.5
Hydroxybupropion	20	4.4	102.9	4.0	107.7	4.6	100.6
	50	2.6	108.8	1.9	112.1	5.3	116.0
	150	2.7	95.2	1.9	104.5	4.6	108.3
Imipramine	100	3.1	109.4	4.1	115.6	2.3	96.9
	250	1.1	110.7	2.1	122.5	3.9	112.4
	750	4.1	100.3	4.0	111.4	4.4	95.1
Norfluoxetine	100	5.9	88.9	2.9	99.8	7.0	99.6
	250	6.6	92.4	2.0	97.4	6.3	110.7
	750	6.6	92.0	4.1	100.9	5.2	106.0
Nortriptyline	100	4.2	101.9	2.7	117.0	3.9	102.7
	250	5.3	105.1	3.4	119.9	5.8	111.4
	750	4.2	97.4	1.8	112.0	4.2	102.0
Paroxetine	100	7.9	106.8	6.1	107.7	2.6	101.7
	250	6.2	104.2	5.1	105.9	6.7	107.8
	750	4.5	104.4	4.7	100.2	6.2	97.2
Venlafaxine	20	9.7	101.5	7.9	100.4	11.0	98.8
	50	2.3	105.5	3.2	116.3	5.8	110.3
	150	3.5	96.0	3.1	105.2	3.8	99.0

Table 4.
Inter-day Precision and Accuracy

Drug	Concentration (ng/mL)	Inter-day	
		CV (%)	Accuracy (%)
Amitriptyline	100	6.7	102.8
	250	3.5	109.9
	750	5.3	101.0
Bupropion	20	10.5	102.9
	50	5.1	109.8
	150	5.3	100.4
Citalopram	20	6.9	105.4
	50	7.3	106.0
	150	7.8	100.1
Clomipramine	100	5.8	99.9
	250	5.1	102.6
	750	5.3	101.8
Desipramine	100	6.4	101.1
	250	5.1	108.5
	750	6.5	99.6
o-Desmethylvenlafaxine	20	6.2	105.3
	50	3.8	115.8
	150	6.3	104.4
Doxepin	100	4.6	107.4
	250	3.5	116.0
	750	4.1	102.0
Duloxetine	100	6.7	108.5
	250	7.2	110.9
	750	6.9	101.5



Table 4. (continued)
Inter-day Precision and Accuracy

Drug	Concentration (ng/mL)	Inter-day	
		CV (%)	Accuracy (%)
Fluoxetine	100	6.9	100.3
	250	7.1	102.5
	750	6.3	102.9
Hydroxybupropion	20	5.0	103.7
	50	4.3	112.3
	150	6.2	103.2
Imipramine	100	8.1	107.3
	250	5.3	115.2
	750	8.1	102.4
Norfluoxetine	100	7.5	96.1
	250	9.4	100.1
	750	7.5	100.2
Nortriptyline	100	7.5	107.2
	250	7.2	112.1
	750	6.8	104.3
Paroxetine	100	6.2	105.4
	250	5.8	106.0
	750	5.6	100.3
Venlafaxine	20	8.9	100.2
	50	5.6	110.7
	150	5.1	100.3

Discussion and Conclusion

Accuracy and precision for all antidepressants and metabolites in reportable range were obtained. The intra-day and inter-day variability was less than 20 %. Negative cut-off values and reportable ranges for urinary analysis can be acceptable.

A new method for detecting 10 antidepressants and 5 of their major metabolites in urine using ultra-high performance liquid chromatography – tandem mass spectrometer (UHPLC-MS), and “dilute-shoot” sample extraction procedures has been established and validated. This assay is suitable for the confirmatory test of the patient antidepressant drug compliance.

Ordering Information

Kinetex[®] Core-Shell HPLC/UHPLC Columns

5 μ m Minibore Columns (mm)			SecurityGuard [™] ULTRA Cartridges [†]
Phases	50 x 2.1	100 x 2.1	3/pk
C18	00B-4601-AN	00D-4601-AN	AJ0-8782 for 2.1 mm ID

5 μ m MidBore [™] Columns (mm)			SecurityGuard ULTRA Cartridges [†]
Phases	50 x 3.0	100 x 3.0	3/pk
C18	00B-4601-Y0	00D-4601-Y0	AJ0-8775 for 3.0 mm ID

5 μ m Analytical Columns (mm)					SecurityGuard ULTRA Cartridges [†]
Phases	50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	3/pk
C18	00B-4601-E0	00D-4601-E0	00F-4601-E0	00G-4601-E0	AJ0-8768 for 4.6 mm ID

2.6 μ m Minibore Columns (mm)						SecurityGuard ULTRA Cartridges [†]
Phases	30 x 2.1	50 x 2.1	75 x 2.1	100 x 2.1	150 x 2.1	3/pk
C18	00A-4462-AN	00B-4462-AN	00C-4462-AN	00D-4462-AN	00F-4462-AN	AJ0-8782 for 2.1 mm ID

2.6 μ m MidBore [™] Columns (mm)						SecurityGuard ULTRA Cartridges [†]
Phases	30 x 3.0	50 x 3.0	75 x 3.0	100 x 3.0	150 x 3.0	3/pk
C18	00A-4462-Y0	00B-4462-Y0	00C-4462-Y0	00D-4462-Y0	00F-4462-Y0	AJ0-8775 for 3.0 mm ID

2.6 μ m Analytical Columns (mm)						SecurityGuard ULTRA Cartridges [†]
Phases	30 x 4.6	50 x 4.6	75 x 4.6	100 x 4.6	150 x 4.6	3/pk
C18	00A-4462-E0	00B-4462-E0	00C-4462-E0	00D-4462-E0	00F-4462-E0	AJ0-8768 for 4.6 mm ID

1.7 μ m Minibore Columns (mm)					SecurityGuard ULTRA Cartridges [†]
Phases	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
C18	00A-4475-AN	00B-4475-AN	00D-4475-AN	00F-4475-AN	AJ0-8782 for 2.1 mm ID

1.7 μ m MidBore Columns (mm)			SecurityGuard ULTRA Cartridges [†]
Phases	50 x 3.0	100 x 3.0	3/pk
C18	00B-4475-Y0	00D-4475-Y0	AJ0-8775 for 3.0 mm ID

[†] SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000

Kinetex Core-Shell Technology HPLC/UHPLC columns also come in a variety of other particle sizes and stationary phases. For more info, please visit www.phenomenex.com/Kinetex

guarantee

If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to other products of the same phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.



APPLICATIONS

Australia

t: 02-9428-6444
f: 02-9428-6445
auinfo@phenomenex.com

Austria

t: 01-319-1301
f: 01-319-1300
anfrage@phenomenex.com

Belgium

t: 02 503 4015 (French)
t: 02 511 8666 (Dutch)
f: +31 (0)30-2383749
beinfo@phenomenex.com

Canada

t: (800) 543-3681
f: (310) 328-7768
info@phenomenex.com

Denmark

t: 4824 8048
f: +45 4810 6265
nordicinfo@phenomenex.com

Finland

t: 09 4789 0063
f: +45 4810 6265
nordicinfo@phenomenex.com

France

t: 01 30 09 21 10
f: 01 30 09 21 11
franceinfo@phenomenex.com

Germany

t: 06021-58830-0
f: 06021-58830-11
anfrage@phenomenex.com

India

t: 040-3012 2400
f: 040-3012 2411
indiainfo@phenomenex.com

Ireland

t: 01 247 5405
f: +44 1625-501796
eireinfo@phenomenex.com

Italy

t: 051 6327511
f: 051 6327555
italiainfo@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
f: +31 (0)30-2383749
nlinfo@phenomenex.com

Mexico

t: 001-800-844-5226
f: 001-310-328-7768
tecnicomx@phenomenex.com

The Netherlands

t: 030-2418700
f: 030-2383749
nlinfo@phenomenex.com

New Zealand

t: 09-4780951
f: 09-4780952
nzinfo@phenomenex.com

Norway

t: 810 02 005
f: +45 4810 6265
nordicinfo@phenomenex.com

Puerto Rico

t: (800) 541-HPLC
f: (310) 328-7768
info@phenomenex.com

Sweden

t: 08 611 6950
f: +45 4810 6265
nordicinfo@phenomenex.com

United Kingdom

t: 01625-501367
f: 01625-501796
ukinfo@phenomenex.com

United States

t: (310) 212-0555
f: (310) 328-7768
info@phenomenex.com

All other countries: Corporate Office USA

t: (310) 212-0555
f: (310) 328-7768
info@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Tomtec and Quadra 4 are trademarks of Tomtec. Shimadzu is a registered trademark and Nexera is a trademark of Shimadzu Corporation. API.3200 and scheduled MRM are trademarks of AB SCIEX Pte, Ltd. AB SCIEX is being used under license. Kinetex is a registered trademark and SecurityGuard is a trademark of Phenomenex.

Disclaimer

The products mentioned are not intended for clinical use. Because they are not intended for clinical use, no claim or representation is made or intended for their clinical use (including, but not limited to diagnostic, prognostic, therapeutic or blood banking). It is the user's responsibility to validate the performance of Phenomenex products for any particular use, since the performance characteristics are not established. Phenomenex products may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system as required by the Clinical Laboratory Improvements Amendments of 1988 (CLIA '88) regulation in the U.S. or equivalent in other countries.

© 2014 Phenomenex, Inc. All rights reserved.